JMB-HEADER RAS-JOURNALS EIMB Pleiades Publishing

RUS

             

ENG

YearIMPACT-FACTOR
2022  1,200
2021  1,540
2020  1,374
2019  1,023
2018  0,932
2017  0,977
2016  0,799
2015  0,662
2014  0,740
2013  0,739
2012  0,637
2011  0,658
2010  0,654
2009  0,570
2008  0,849
2007  0,805
2006  0,330
2005  0,435
2004  0,623
2003  0,567
2002  0,641
2001  0,490
2000  0,477
1999  0,762
1998  0,785
1997  0,507
1996  0,518
1995  0,502
Vol 49(2015) N 1 p. 48-57; DOI 10.1134/S0026893315010161 Full Text

V.V. Vlassov1, E.Yu. Rykova1*, A.A. Ponomaryova2,4, I.A. Zaporozhchenko1, E.S. Morozkin1, N.V. Cherdyntseva2,3, P.P. Laktionov1

Circulating microRNAs in lung cancer: prospects for diagnosis, prognosis, and prediction of antitumor treatment efficacy

1Institute of Chemical Biology and Fundamental Medicine, Siberian Branch, Russian Academy of Sciences, Novosibirsk, 630090 Russia
2Tomsk Cancer Research Institute, Tomsk, 634009 Russia
3National Research Tomsk State University, Tomsk, 634050 Russia
4National Research Polytechnic University, Tomsk, 634050 Russia

*rykova@niboch.nsc.ru
Received - 2014-07-17; Accepted - 2014-08-13

The review considers the main techniques to extract microRNA (miRNA) from various biological fluids (in particular, the serum and plasma), approaches to the analysis of miRNA concentration and composition, and methods to normalize the results in data analyses. Advantages and drawbacks of the methods are described. Special attention is given to circulating miRNAs, which can be used as markers for minimally invasive diagnosis, prediction of antitumor treatment efficacy, and disease prognosis in lung cancer. The review discusses the prospects and limitations that arise as the clinical significance is evaluated for miRNAs as potential tumor markers and a better understanding is gained for the roles various miRNAs play in the pathogenesis of lung cancer.

lung cancer, diagnosis, prognosis, tumor markers, circulating microRNAs



JMB-FOOTER RAS-JOURNALS